Clinical Trials Logo

Abnormal Glucose Tolerance clinical trials

View clinical trials related to Abnormal Glucose Tolerance.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04731272 Recruiting - Diabetes Clinical Trials

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions to preserve β-cell function are crucial for delaying and potentially preventing CFRD development. In this study, we hypothesize that weekly administration of the long-acting glucagon-like peptide-1 (GLP-1) agonist dulaglutide will improve defective early-phase insulin secretion and improve glucose tolerance during a mixed-meal tolerance test.